Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Various classes of antidepressant medications generally induce remission of major depressive disorder in only about one-third of patients. In a previous study using mirtazapine or paroxetine alone or in combination from treatment initiation, the rate of patients who remitted within a 6-week period was twice that of patients using either drug alone. In this double-blind study, the authors sought to produce evidence for the superiority of different combinations of antidepressant drugs from treatment initiation. METHOD: Patients (N=105) meeting DSM-IV criteria for major depressive disorder were randomly assigned to receive, from treatment initiation, either fluoxetine monotherapy (20 mg/day) or mirtazapine (30 mg/day) in combination with fluoxetine (20 mg/day), venlafaxine (225 mg/day titrated in 14 days), or bupropion (150 mg/day) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HAM-D) score. RESULTS: The overall dropout rate was 15%, without notable differences among the four groups. Compared with fluoxetine monotherapy, all three combination groups had significantly greater improvements on the HAM-D. Remission rates (defined as a HAM-D score of 7 or less) were 25% for fluoxetine, 52% for mirtazapine plus fluoxetine, 58% for mirtazapine plus venlafaxine, and 46% for mirtazapine plus bupropion. Among patients who had a marked response, double-blind discontinuation of one agent produced a relapse in about 40% of cases. CONCLUSIONS: The combination treatments were as well tolerated as fluoxetine monotherapy and more clinically effective. The study results, which add to a growing body of evidence, suggest that use of antidepressant combinations from treatment initiation may double the likelihood of remission compared with use of a single medication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Keller, M. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100053010 · Cited by 864
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
The Role of the Primary Care Physician in Patientsʼ Adherence to Antidepressant Therapy
LIN, E. H. B., KORFF, M. V., KATON, W., BUSH, T., SIMON, G. E., WALKER, E., & ROBINSON, P. (1995) · Medical Care · doi:10.1097/00005650-199501000-00006 · Cited by 587 · cited 1×
“Considering that about half of all patients stop their antidepressant drug within this time frame (6, 7), it is clear that initial treatment steps are critical to achieving the goal of remission.”
BackgroundJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458 · cited 1×
“It is recognized, however, that leaving patients with residual symptoms predisposes them to a full relapse of depression within a much shorter time than if remission were achieved (4, 5).”
BackgroundMelfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1128 · Cited by 409 · cited 1×
“Considering that about half of all patients stop their antidepressant drug within this time frame (6, 7), it is clear that initial treatment steps are critical to achieving the goal of remission.”
BackgroundWeight gain and antidepressants.
D, M. F. M. (2000) · PubMed · Cited by 388
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measures
Carmody, T. J., Rush, A. J., Bernstein, I., Warden, D., Brannan, S., Burnham, D., Woo, A., & Trivedi, M. H. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.008 · Cited by 245
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Nelson, J. C., Mazure, C. M., Jatlow, P. I., Bowers, M. B., & Price, L. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.007 · Cited by 189
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.027 · Cited by 183
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.015 · Cited by 161
Self-citationDifferential physiological effects of a low dose and high doses of venlafaxine in major depression
Debonnel, G., Saint-André, É., Hébert, C., de Montigny, C., Lavoie, N., & Blier, P. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006413 · Cited by 147
Self-citationMaes, M., Libbrecht, I., van Hunsel, F., Campens, D., & Meltzer, H. Y. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00014 · Cited by 133
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2010) · Focus · doi:10.1176/foc.8.4.foc592 · Cited by 126
Haddjeri, N., Blier, P., & de Montigny, C. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12944-3 · Cited by 124
Self-citationFava, M., Dunner, D. L., Greist, J. H., Preskorn, S. H., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0603 · Cited by 94
Lam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Reimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80060-x · Cited by 79
Besson, A., Haddjeri, N., Blier, P., & de Montigny, C. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00069-9 · Cited by 76
Self-citationHaddjeri, N., Blier, P., & de Montigny, C. (1996) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00004913 · Cited by 76
Self-citationDong, J.-M., & Blier, P. (2001) · Psychopharmacology · doi:10.1007/s002130000665 · Cited by 48
Self-citationAntidepressants in clinical practice: limitations of assessment methods and drug response
Kennedy, S. H., Eisfeld, B. S., Meyer, J. H., & Bagby, R. M. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.189 · Cited by 36
Shams, M. E. E., Hiemke, C., & Härtter, S. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200402000-00015 · Cited by 33
New goals in the treatment of depression: moving toward recovery.
Thase, M. E., & Ninan, P. T. (2002) · PubMed · Cited by 30
Research works printed but not linked: 5
- First MB, 1994, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
- Aldosary F, 2007, American College of Neuropsychopharmacology, 46th annual meeting, General Program, 254
- Thase ME, 2002, Psychopharmacol Bull, 36, 24
- Fava M, 2000, J Clin Psychiatry, 61, 37
- Wahlbeck K, 2000, Cochrane Database Syst Rev, 2, CD000059
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“A double-blind randomised trial where patients were treated with combinations of mirtazapine with fluoxetine, venlafaxine or buproprion showed that these were more effective for depression than fluoxetine monotherapy and that they were well tolerated (Blier et al., 2010).”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“One small study found considerable benefit from combining mirtazapine with fluoxetine, venlafaxine or bupropion compared with fluoxetine alone (Blier et al., 2010).”
BackgroundMonoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Yet, in another study, combination treatment involving mirtazapine, fl uoxetine, venlafaxine, and bupropion was clearly superior to fl uoxetine monotherapy (Blier et al. 2010).”
Result
Metadata
- Authors
- Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R.
- Affiliations
- University of Ottawa (CA)
- Venue
- American Journal of Psychiatry
- Published
- 2010-03-01
- Volume
- 167
- Issue
- 3
- Pages
- 281-288
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2151590183
- Cited by
- 316
- References
- 32
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 15 · 2021: 27 · 2020: 14 · 2019: 12 · 2018: 11 · 2017: 8 · 2016: 24 · 2015: 28 · 2014: 17 · 2013: 34 · 2012: 32
- FWCI
- 24.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- major depressive disorder, antidepressant combination therapy, mirtazapine, fluoxetine, venlafaxine, bupropion, remission, treatment initiation, relapse after treatment discontinuation, antidepressant efficacy, tolerability
- MeSH terms
- Venlafaxine Hydrochloride, Mirtazapine, Adult, Antidepressive Agents, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Mianserin, Middle Aged, Personality Inventory, Psychometrics, Bupropion, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.